2:45 pm Harnessing GLP-1s to Maximize MASH Treatment Effectiveness to Expand the Therapeutic Benefits of This Class of Drugs
Time: 2:45 pm
day: Conf day 2
Details:
- Reviewing GLP-1 mechanisms, including the unique biological actions of GLP-1 receptor agonists in targeting key pathways of MASH pathogenesis to demonstrate their potential to improve liver health to offer a novel therapeutic avenue for MASH patients
- Presenting GLP-1 clinical evidence in MASH patients to demonstrate significant improvements in histological endpoints and metabolic profiles to establish their efficacy in treating the disease
- Discussing expanded GLP-1 applications to explore how the versatility of GLP-1s in addressing multiple comorbidities can expand their therapeutic benefits beyond the liver to offer a holistic treatment approach for MASH patients and improving their overall health
